🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A wonderful evening at the IBUS Members Meeting in Berlin! Great venue, happy guests, and special moments. Congrats to Polychronis Pavlidis for winning the ECCO IBUS Grant! And of course: A heartfelt thank you to Frauke Petersen, our honorary IBUS member. #IBUS #ECCO

Differentiating clinical characteristics of perianal inflammatory bowel disease from perianal hidradenitis suppurativa - Yamanaka‐Takaichi - 2025 - International Journal of Dermatology - Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/ij… afsaneh alavi

#ECCO2025 Multi society consensus on diagnostic and monitoring This 👇is perhaps the most relevant relating to treatment withdrawal - pragmatic and sustainable

This is part of my presentation entitled 'Access to medication in Asia' at ECCO2025. What solutions do you think could drive equitable access to treatments globally? #ECCO #ECCO2025 Flavio Dr. Rupa Banerjee Dr Yoon-Kyo An Ren Mao，MD，PhD Partha Pal Byong Duk Ye Alex Leow Wai K Leung

If you’re an HCP taking care of patients with #IBD please fill out this survey to better understand access to #IBD care in different regions of the 🌍 Your voice is important! Badr Al-Bawardy Aline Charabaty, MD, FACG, AGAF Waqqas Afif, MD Florian Rieder Miguel Regueiro Keith Siau Sophie Restellini Charlie Murray

Honored to see that our HAYABUSA is included!

Happy to join DR FALK symposium in City of Sydney with #IBD friends! Dr Yoon-Kyo An Taku Kobayashi Johan Burisch David T. Rubin, MD

A substantial proportion of patients with CD exhibited ulcerations in the proximal ileum, which correlated with a poorer prognosis. These lesions proved challenging to heal, regardless of the type of biologic used. authors.elsevier.com/c/1ktXG_Z4R9HU…

Acute Severe Ulcerative Colitis: An International Delphi Consensus on Clinical Trial Design and Endpoints　Vipul Jairath MBChB DPhil Peter Higgins Seb Byong Duk Ye Paulo G. Kotze Jonas Halfvarson Laurent Peyrin-Biroulet doi.org/10.1016/j.cgh.…

Our real-world experience of mirikizumab in UC including patients with prior exposure to ustekinumab has been published. doi.org/10.1111/apt.70…

I had the opportunity to attend a wonderful lecture in Tokyo by Dr. Christopher Ma from the University of Calgary. His talk provided valuable insights, and the discussion among participants was truly stimulating. Grateful for this enriching experience. Thank you, Chris.

Over a decade since I collaborated with world-class epidemiologist Gil Kaplan MD MPH and his team, here is our long awaited paper out in nature reporting for the first time evolution of #ibd across 4 stages Helmsley Charitable Trust IOIBD CUHK Medicine GIVES-21 nature.com/articles/s4158…

Anti-alpha-v-beta6 auto-antibodies may predict UC #colitis outcomes with advanced therapy somewhat independent of disease activity (CRP). Interesting finding: auto-antibody levels inversely related to disease duration #DDW2025 #IBD

Deucravacitinib in Patients With #IBD: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn’s Disease and Ulcerative Colitis academic.oup.com/ecco-jcc/artic… Remo Panaccione, MD, FRCPC Laurent Peyrin-Biroulet Y-ECCO Taku Kobayashi

Our letter published in Gut Journal comparing the 4 RCTs of anti-TNF withdrawal in #IBD in light of the EXIT trial. DrShahidaDin Taku Kobayashi Aaron Bancil Nikolas Plevris gut.bmj.com/cgi/rapidpdf/g…

2nd international webinar on #IBD

Wonderful program at APAGE Clinical Forum on IBD in Penang! Met new and old friends across Asia! See you next year in Bangkok2026.

Real-World Effectiveness and Safety of Mirikizumab Induction Therapy in Patients With Ulcerative Colitis: A Multicentre Retrospective Observational Study onlinelibrary.wiley.com/doi/10.1111/ap…

Real‐World Effectiveness and Safety of Vedolizumab in Patients ≥ 70 Versus < 70 Years With Ulcerative Colitis: Multicenter Retrospective Study onlinelibrary.wiley.com/doi/10.1111/jg…

Time to EXIT? Our editorial on the EXIT study has been published. onlinelibrary.wiley.com/doi/pdf/10.111…